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s u m m a r y 
Background: Screening for SARS-CoV-2 antibodies is under way in some key worker groups; how this 
adds to self-reported COVID-19 illness is unclear. In this study, we investigate the association between 
self-reported belief of COVID-19 illness and seropositivity. 
Methods: Cross-sectional study of three key worker streams comprising (A) Police and Fire & Rescue 
(2 sites) (B) healthcare workers (1 site) and (C) healthcare workers with previously positive PCR result 
(5 sites). We collected self-reported signs and symptoms of COVID-19 and compared this with serology 
results from two SARS-CoV-2 immunoassays (Roche Elecsys® and EUROIMMUN). 
Results: Between 01 and 26 June, we recruited 2847 individuals (Stream A: 1,247, Stream B: 1,546 and 
Stream C: 154). Amongst those without previous positive PCR tests, 687/2,579 (26%) reported belief 
they had COVID-19, having experienced compatible symptoms; however, only 208 (30.3%) of these were 
seropositive on both immunoassays. Both immunoassays had high sensitivities relative to previous PCR 
positivity ( > 93%); there was also limited decline in antibody titres up to 110 days post symptom on- 
set. Symptomatic but seronegative individuals had differing sym ptom profiles and shorter illnesses than 
seropositive individuals. 
Conclusion: Non-COVID-19 respiratory illness may have been mistaken for COVID-19 during the outbreak; 
laboratory testing is more specific than self-reported key worker beliefs in ascertaining past COVID-19 
disease. 
Crown Copyright © 2021 Published by Elsevier Ltd on behalf of The British Infection Association. 
This is an open access article under the CC BY-NC-ND license 
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After SARS-CoV-2 infection, most individuals mount antibody 
esponses. 1–6 Serological tests aim to identify people who have ection Association. This is an open access article under the CC BY-NC-ND license 














































































































reviously been infected, through detection of anti-SARS-CoV-2 an- 
ibodies. 7 Currently, serological tests are important in helping us 
etter understand how the disease has spread in the population, 
nd can support pandemic planning and response. 8 In the future 
hey may also be used for individual risk assessment; however at 
resent, although antibody titre correlate with in vitro neutralisa- 
ion 1 , 3 and clinical studies suggest an antibody-protection associa- 
ion, 9 it has not yet been proven whether presence of antibody in- 
icates protection against future infection; as such, the usefulness 
f serology testing in clinical practice is currently unclear. 
Early in the response to the epidemic, PCR testing was re- 
tricted to those needing hospital care. As testing provision rose, 
est availability was progressively extended to include health care 
orkers, and (less extensively) to other key worker groups such 
s Police officers. Only in the latter stages of the first wave of 
nfection was widespread community testing available to all who 
eveloped symptoms; initially this was restricted only to those 
ith fever or cough. Collectively, this may have resulted in parts 
f the population believing they have had COVID-19 because of 
llness during the pandemic, some of whom may not have had 
he virus. However, the validity of this understandable assump- 
ion, and whether it is justified given particular symptom combi- 
ations, is poorly quantified. Although some COVID-19 symptoms, 
uch as taste/smell disorders, are highly specific for COVID-19, 10 
any others occur in other viral respiratory infections, and a re- 
ent Cochrane review has highlighted the substantial uncertainty 
bout the value of clinical symptoms in the diagnosis of COVID- 
9. 11 Several studies have looked at the association between in- 
ividual symptoms and seropositivity, 12 , 13 identifying associations 
ith symptoms such as anosmia and ageusia and seropositivity; 
owever, to our knowledge, no study has assessed the relationship 
etween self-reported belief of previous COVID-19, combinations 
f signs and symptoms, and seropositivity. 
The UK Government recently launched a mass antibody test- 
ng programme for staff in the National Health Service (NHS) and 
or care workers. 14 Large scale testing on historical sera has in- 
icated a very high specificity of the assays used, 15 but concerns 
ave been raised about a lack of data on assay performance > 35 
ays post infection, 7 in community cases (particularly those that 
id not meet testing criteria early in the response), and serological 
esponses which may be of short duration. 16 
Here we address existing uncertainties as to value of symp- 
oms 11 in diagnosing historical COVID-19 infection. To do this, we 
i) describe patterns of self reported symptoms in a cohort of key 
orkers, (ii) describe serostatus in individuals > 35 days post in- 
ection, in a cohort recruited about 2–3 months after the outbreak 
eak of the initial wave of COVID-19 infections in the UK, and (iii) 
nalyse relationships between serostatus and self reported symp- 
oms. 
aterials and methods 
tudy population 
The study population consists of various key workers, who are 
nticipated to be the initial users of UK government home anti- 
ody testing programme. Key workers were targeted for recruit- 
ent as part of the Evaluating Detection of SARS-CoV-2 AntiBodies 
t HOME (EDSAB-HOME) study (clinical trial registration: http:// 
ww.isrctn.com/ISRCTN56609224 ), a programme designed to eval- 
ate the accuracy of point of care antibody tests. 
ecruitment and data collection 
We recruited three streams of key workers (A) Police and Fire 
 Rescue “Police and Fire” (B) healthcare workers “HCW” and; (C) 152 ealthcare workers who had a previous positive nasal or throat 
wab for SARS-CoV-2 (with or without symptoms) “HCW-PP” and 
herefore are confirmed to have had previous COVID-19. In this pa- 
er, our focus is on the relationship between prior signs and symp- 
oms and seropositivity. 
Prospective workplace based recruitment was conducted be- 
ween 01 and 26 June 2020. Senior staff in the NHS, Police and Fire 
rganisations were invited to a telephone conversation in which 
he study was described and invited to support the study. Those 
ho agreed to take part in the study were sent an ethically ap- 
roved advert by email to all staff. Individuals interested in the 
tudy were directed to an online study portal, where they com- 
leted an epidemiological questionnaire, and booked to attend a 
orkplace clinic; availability was given on a first-come-first-served 
asis. At the clinic appointment, a venous blood sample was taken, 
hich was linked back to their questionnaire via a unique study 
umber. Further methodological details are in Supplementary Ma- 
erial. 
erological analysis 
A volume of 6 mL EDTA anticoagulated blood was taken from 
ach participant and sent to PHE Seroepidemiology Unit (SEU) 
n Manchester each day for plasma separation and sample bank- 
ng. An aliquot of the samples was sent to PHE Porton Down for 
nalysis. All samples were analysed using Roche Elecsys® Anti- 
ARS-CoV-2 (nucleocapsid (N)) 15 and EUROIMMUN Anti-SARS-CoV- 
 ELISA (IgG) assays (Spike (S) protein S1 domain). 17 Further details 
n sample receipt, storage and processing is available in Supple- 
entary Material. 
Manufacturer cut-offs were used to assess serological positivity 
COI ≥ 1.0 for Roche Elecsys® and Ratio > 0.8 for EUROIMMUN 
ere considered positive) (Further details in Supplementary Mate- 
ial). For the purpose of assessing the relationship between clinical 
igns and symptoms and seropositivity and estimating seropreva- 
ence amongst sub-cohorts, an individual was considered seropos- 
tive if they were positive on either immunoassay. 
uestionnaire and categorisation of individuals 
All data were collected via an online questionnaire (Snap Sur- 
ey), and were stored and managed on a secure server using a 
elational database management system (SQL). Data were cleaned 
nd analysed using R version 3.5.1. Participants were characterised 
nd reported by an adapted version of the World Health Organiza- 
ion (WHO) criteria for confirmed, suspected and probable cases. 18 
hese definitions were pre-specified; further details are in Supple- 
entary Material. 
tatistical analysis 
(i) To describe patterns of self reported symptoms in the cohort 
e: (a) performed univariable description of the cohort by age, 
ender, ethnicity, occupation, recent symptoms compatible with 
OVID-19 and previous known exposure to SARS-CoV-2 and by re- 
ults on the two anti-SARS-CoV-2 immunoassays. Comparison was 
ade with laboratory confirmed COVID-19 data for England ob- 
ained from data.coronavirus.gov.uk on 28 July 2020. 
(b) To consider the relationships between different self reported 
ymptoms, we coded symptoms as 1 (present) or 0 (not present). 
e computed a matrix of Pearson correlation coefficients reflect- 
ng co-existence of pairs of symptoms, both for personal symptoms 
nd for those reported in household contacts. To illustrate patterns 
n this data, we performed hierarchical clustering of the correla- 
ion matrix using Euclidean distance metric and central cluster- 
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Table 1 
Demographics and exposure characteristics, split by recruitment group 
Stream A: Police and Fire 
Stream B: Healthcare 
workers (HCW) 




18 – 25 37 (3.2%) 89 (5.8%) 13 (8.4%) 139 (4.9%) 
25 – 40 420 (36.6%) 586 (37.9%) 62 (40.3%) 1068 (37.5%) 
40 – 60 660 (57.5%) 747 (48.3%) 71 (46.1%) 1478 (51.9%) 
60 + 30 (2.6%) 124 (8.0%) 8 (5.2%) 162 (5.7%) 
Sex 
Female 455 (39.7%) 1247 (80.7%) 126 (81.8%) 1828 (64.2%) 
Male 692 (60.3%) 299 (19.3%) 28 (18.2%) 1019 (35.8%) 
Ethnicity 
White 1085 (94.6%) 1128 (73.0%) 137 (89.0%) 2350 (82.5%) 
Asian or British Asian 33 (2.9%) 237 (15.3%) 11 (7.1%) 281 (9.9%) 
Black or Black British 2 (0.2%) 96 (6.2%) 1 (0.6%) 99 (3.5%) 
Mixed 21 (1.8%) 42 (2.7%) 3 (1.9%) 66 (2.3%) 
Other 6 (0.5%) 43 (2.8%) 2 (1.3%) 51 (1.8%) 
Occupation 
First responder – police 528 (46.0%) 0 (0.0%) 0 (0.0%) 528 (18.5%) 
First responder – fire & rescue 238 (20.7%) 0 (0.0%) 0 (0.0%) 238 (8.4%) 
First responder – other (e.g. ambulance) 40 (3.5%) 1 (0.1%) 0 (0.0%) 41 (1.4%) 
Hospital doctor 0 (0.0%) 245 (15.8%) 41 (26.6%) 286 (10.0%) 
Hospital nurse 1 (0.1%) 471 (30.5%) 51 (33.1%) 523 (18.4%) 
Hospital medical other 0 (0.0%) 249 (16.1%) 18 (11.7%) 267 (9.4%) 
Hospital non-medical 0 (0.0%) 158 (10.2%) 9 (5.8%) 167 (5.9%) 
Hospital lab based 0 (0.0%) 35 (2.3%) 1 (0.6%) 36 (1.3%) 
GP doctor/nurse/other 0 (0.0%) 20 (1.3%) 4 (2.6%) 24 (0.8%) 
Community nurse 0 (0.0%) 36 (2.3%) 9 (5.8%) 45 (1.6%) 
NHS staff other 0 (0.0%) 309 (20.0%) 20 (13.0%) 329 (11.6%) 
Other 340 (29.6%) 22 (1.4%) 1 (0.6%) 363 (12.8%) 
Interacted face-to-face with patients and/or general public during lockdown (post-23 March) 
More frequently than before lockdown 24 (2.1%) 161 (10.4%) 13 (8.4%) 198 (7.0%) 
Similar to before lockdown 494 (43.1%) 671 (43.4%) 91 (59.1%) 1256 (44.1%) 
Less frequently than before lockdown 418 (36.4%) 564 (36.5%) 40 (26.0%) 1022 (35.9%) 
No such interactions 39 (3.4%) 28 (1.8%) 2 (1.3%) 69 (2.4%) 
Non-response 172 (15.0%) 122 (7.9%) 8 (5.2%) 302 (10.6%) 
Do you think you have had previous COVID-19? 
Yes, I had symptoms but was not tested 225 (19.6%) 301 (19.5%) 0 (0.0%) 526 (18.5%) 
Yes, I had symptoms but my test(s) were all negative 41 (3.6%) 112 (7.2%) 0 (0.0%) 153 (5.4%) 
Yes, I had symptoms, and I had at least one positive test 24 (2.1%) 80 (5.2%) 152 (98.7%) 256 (9.0%) 
Yes, I had symptoms, had a test, but it failed 5 (0.4%) 3 (0.2%) 0 (0.0%) 8 (0.3%) 
I did not recognise that I had symptoms, but I tested positive when I 
was screened 
0 (0.0%) 10 (0.6%) 2 (1.3%) 12 (0.4%) 
No 557 (48.6%) 648 (41.9%) 0 (0.0%) 1205 (42.3%) 
Unsure 295 (25.7%) 392 (25.4%) 0 (0.0%) 687 (24.1%) 
Length of symptoms ∗
Less than 7 days 115 (39.1%) 178 (36.1%) 30 (19.7%) 323 (34.4%) 
7 -14 days 121 (41.2%) 185 (37.5%) 63 (41.4%) 369 (39.3%) 
14 – 21 days 27 (9.2%) 66 (13.4%) 27 (17.8%) 120 (12.8%) 
More than 21 days 28 (9.5%) 58 (11.8%) 30 (19.7%) 116 (12.4%) 
Do not know 3 (1.0%) 6 (1.2%) 2 (1.3%) 11 (1.2%) 
Unable to work (in workplace or at home) due to symptoms ∗
Yes 191 (65.0%) 350 (71.0%) 144 (94.7%) 685 (72.9%) 
No 103 (35.0%) 143 (29.0%) 8 (5.3%) 254 (27.1%) 
Went to hospital due to suspected/confirmed COVID-19 ∗
Yes 4 (1.4%) 19 (3.9%) 15 (9.9%) 901 (96.0%) 
No 290 (98.6%) 474 (96.1%) 137 (90.1%) 38 (4.0%) 
Was in contact with a suspected or confirmed case in the 14-day prior to symptom onset ∗
Yes, confirmed 23 (7.8%) 153 (31.0%) 92 (60.5%) 485 (51.7%) 
Yes, suspected 47 (16.0%) 113 (22.9%) 26 (17.1%) 268 (28.5%) 
No/Unsure 224 (76.2%) 227 (46.0%) 34 (22.4%) 186 (19.8%) 
Has had a SARS-CoV-2 antibody test, and been informed of the result prior to recruitment 
Yes 4 (0.3%) 20 (1.3%) 68 (44.2%) 92 (3.2%) 
No 1143 (99.7%) 1523 (98.5%) 86 (55.8%) 2752 (96.7%) 
Did not answer 0 (0.0%) 3 (0.2%) 0 (0.0%) 3 (0.1%) 
Had a household member who had COVID-19 compatible symptoms 
Yes 289 (25.2%) 396 (25.6%) 83 (53.9%) 768 (27.0%) 
No 858 (74.8%) 1150 (74.4%) 71 (46.1%) 2079 (73.0%) 
Had a household member who had SARS-CoV-2 positive nasal or throat swab 
Yes 21 (1.8%) 44 (2.8%) 32 (20.8%) 97 (3.4%) 
No 1126 (98.2%) 1502 (97.2%) 122 (79.2%) 2750 (96.6%) 
WHO criteria 
Confirmed (had a positive nasal or throat swab) 24 (2.1%) 90 (5.8%) 154 (100.0%) 268 (9.4%) 
Suspected 158 (13.8%) 238 (15.4%) 0 (0.0%) 396 (13.9%) 
Early-probable 72 (6.3%) 73 (4.7%) 0 (0.0%) 145 (5.1%) 
Uncertain 40 (3.5%) 105 (6.8%) 0 (0.0%) 145 (5.1%) 
No 853 (74.4%) 1040 (67.3%) 0 (0.0%) 1893 (66.5%) 
Total 1147 1546 154 2847 
∗ for only those who self-reported COVID-19 compatible symptoms. In addition, variables where the participant did not respond (NAs) amongst those who reported 
symptoms were not included (1 in Police and Fire and 3 in HCW). Final total was 939, split across Police and Fire (n = 295), HCW (n = 496) and HCW-PP (n = 152). 
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ng. 19 and depicted the reassorted matrix as a heatmap. We used 
he R hclust and corrplot functions to achieve this. 
(ii) To describe the serostatus of individuals, we (a) tabulated 
ssociations with single clinical risk factors and serostatus; (b) 
sed Spearman’s rank correlation coefficient to assess the concor- 
ance between the two laboratory immunoassay performed; (c) 
xplored the relationship between symptom onset and quantitative 
erological response graphically and modelled relationships using 
inear quantile regression (implemented in the R quantreg package) 
o test for evidence for a change over time; and (d) assessed the 
elationship between duration of symptoms (described as a cate- 
orical variable) and antibody assay signal (a continuous variable) 
sing Kendall’s correlation coefficient. 
(iii) To describe relationships between serostatus and self re- 
orted symptoms, we (a) computed unadjusted odds ratios (ORs) 
ith 95% confidence intervals (95% CIs) favouring seropositivity 
iven various clinical risk factors for those in Police and Fire 
nd HCW groups using binary logistic regression, and (b) esti- 
ated sensitivity of the immunoassays as the proportion of con- 
rmed cases (individuals who had a previously PCR-positive nasal 
r throat swab) with detectable SARS-CoV-2 antibodies. 
esults 
ecruitment 
Recruitment opened on 27 May 2020, and study clinics ran 
rom 1 June to 26 June 2020 in two non-healthcare worker sites 
one Police and one Fire & Rescue) and in six NHS acute hospitals 
n England (Supplementary Figure 1). 3087 individuals completed a 154 uestionnaire, of whom 2867 (93%) attended a clinic appointment 
nd were successfully enrolled into the study. We excluded indi- 
iduals due to non-eligibility ( n = 1, who was recruited in “Stream 
” however did not have a previously positive PCR result), techni- 
al issues (e.g. insufficient sample) preventing blood samples being 
nalysed ( n = 14), and withdrawals from the study after recruit- 
ent ( n = 5). There were no test failures on either immunoassay. 
he final cohort contained 2847 individuals: 1147 from Police and 
ire (Stream A); 1546 health care workers (HCW) (Stream B); and 
54 from the healthcare worker previously COVID-19 positive test 
roup (HCW-PP) (Stream C) ( Figure 1 ). 
ohort description 
Of the 2847 individuals, 36% were male and 64% were female. 
heir ages ranged from 19 to 73 years with a median age of 43 
 Table 1 , Supplementary Figure 2). Ethnicity was majority white 
83%), followed by 10% Asian, 3% Black, 2% Mixed and 2% Other. 
verall 44% reported face to face interactions during lockdown 
ith clients/patients at a similar frequency to pre-lockdown. At the 
ime the questionnaire was administered, only 3% had a COVID-19 
ntibody test and had been informed of the result. All the HCW- 
P group had (by definition) a previously positive SARS-CoV-2 PCR 
esult; by contrast, only 2% of the Police and Fire group and 6% of 
he HCW group had a prior PCR positive result. 
Amongst the 2579 individuals without any prior PCR positivity, 
7% ( n = 687) reported believing they had COVID-19 due to com- 
atible symptoms (Table S1). By group, 29% (416/1456) in HCW and 
4% (271/1123) in Police and Fire groups reported such a belief. 
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Amongst individuals who reported symptoms, the median time 
ince symptoms onset to the EDSAB-HOME recruitment visit was 
5 days (IQR 63 – 92 days), which was on average 12 days longer 
han the time since symptoms amongst the known previous PCR 
ositives (median 63 days). In this cohort, hospitalisation due to 
OVID-19 like illness was unusual, being reported in 1% and 4% of 
ire & Police and HCW groups, respectively ( Table 1 ). 
ymptom correlations 
Some symptoms were commonly reported together ( Figure 3 ). 
or example, altered sense of taste (ageusia) and smell (anosmia) 
ere commonly co-reported; a symptom cluster of breathlessness, 
ough, muscle aching, fever and fatigue was also evident. Reporting 
ymptoms in both these clusters was strongly associated with both 
elief that one had previously had COVID-19, and with seroposi- 
ivity. Much weaker associations with seropositivity and with be- 
ief in prior COVID-19 infection were observed with other symp- 
om clusters identified, and with clusters of symptoms reported in 
ousehold members. 155 eropositivity and its relationship to belief in past COVID-19 infection 
Seropositivity was more common amongst those who reported 
aving had COVID-19 compatible symptoms: amongst those who 
elf-reported COVID-19 compatible symptoms, 28% in Police and 
ire and 50% of HCW were seropositive compared with 5% and 11% 
f those who did not report such symptoms ( Table 2 ). Therefore, 
elf-belief of having had COVID-19 was associated with seroposi- 
ivity, in both the Police and Fire (OR 7.5, 95% CI 5.0–11.3) and in 
CW (OR 7.9, 95% 6.1–10.3). However, of those seropositive across 
oth groups, only 68% thought they had COVID-19 (equating to 32% 
f the seropositives having had asymptomatic COVID-19). 
eropositivity and reported symptoms 
Our study detected seropositivity as associated with several 
nown clinical risk factors ( Table 2 , Figure 3 , Supplementary Figure 
). The association varied for individual symptoms and seropositiv- 
ty, such as altered sense of smell (OR 19.5, 95% CI 14.3–26.9) and 
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Figure 3. Symptoms and symptom clusters as reported by participants. 
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Table 2 
Seropositivity by recruitment group for clinical risk factors ∗
Police and Fire HCW 
Number and percentage of 
individuals who are seropositive N 
(%) OR 
Number and percentage of 
individuals who are seropositive N 
(%) OR 
Belief of previously having had COVID-19 
Yes 81 (27.5%) 7.5 (5.0-11.3) 245 (49.4%) 7.9 (6.1-10.3) 
No 41 (4.8%) ref 115 (11.0%) ref 
Length of symptoms 
Less than 7 days 42 (9.5%) ref 113 (19.4%) ref 
7 -14 days 47 (21.9%) 2.7 (1.7-4.2) 118 (40.1%) 2.8 (2.0-3.8) 
14 – 21 days 12 (22.2%) 2.7 (1.3-5.4) 37 (41.1%) 2.9 (1.8-4.6) 
More than 21 days 12 (19.4%) 2.3 (1.1-4.5) 41 (39.4%) 2.7 (1.7-4.2) 
Unable to work (in workplace or at home) due to symptoms 
Yes 64 (23.3%) 3.0 (2.0-4.5) 208 (41.7%) 3.0 (2.3-3.9) 
No 52 (9.2%) ref 125 (19.2%) ref 
Went to hospital due to suspected/confirmed COVID-19 
Yes 3 (75.0%) 19.2 (2.4-390) 16 (76.2%) 8.2 (3.2-25.2) 
No 113 (13.5%) ref 317 (28.1%) ref 
Was in contact with a suspected or confirmed case in the 14-day prior to symptom onset 
Yes 26 (24.5%) 2.3 (1.4-3.8) 200 (47.4%) 4.0 (3.1-5.3) 
No/Unsure 90 (12.2%) ref 133 (18.3%) ref 
Had a household member who had COVID-19 compatible symptoms 
Yes 62 (21.5%) 3.6 (2.5-5.3) 140 (35.4%) 2.3 (1.8-3.0) 
No 60 (7.0%) ref 220 (19.1%) ref 
Had a household member who had SARS-CoV-2 positive nasal or throat swab 
Yes 8 (38.1%) 5.5 (2.1-13.2) 26 (59.1%) 5.1 (2.8-9.5) 
No 114 (10.1%) ref 334 (22.2%) ref 
WHO criteria 
Confirmed (had a positive nasal or throat swab) 23 (95.8%) 456 (92.5-8250) 87 (96.7%) 253 (92.7-1042) 
Suspected 52 (32.9%) 9.8 (6.2-15.4) 130 (54.6%) 10.5 (7.6-14.6) 
Early-probable 3 (4.2%) 0.9 (0.2-2.5) 12 (16.4%) 1.8 (0.9-3.2) 
Uncertain 3 (7.5%) 1.6 (0.4-4.7) 24 (22.9%) 2.6 (1.6-4.2) 
No 41 (4.8%) ref 107 (10.3%) ref 
Symptom 
A new continuous cough Yes 52 (16.4%) 2.1 (1.4-3.1) 144 (34.5%) 2.2 (1.7-2.9) 
No 70 (8.4%) 216 (19.1%) 
Fever (or high temperature) Yes 53 (22.3%) 3.5 (2.4-5.2) 191 (45.6%) 4.8 (3.7-6.2) 
No 69 (7.6%) 169 (15.0%) 
Shortness of breath Yes 45 (18.0%) 2.3 (1.6-3.5) 115 (35.2%) 2.2 (1.7-2.8) 
No 77 (8.6%) 245 (20.1%) 
Sore throat Yes 45 (10.4%) 1.0 (0.6-1.4) 139 (22.8%) 1.0 (0.8-1.2) 
No 77 (10.8%) 221 (23.6%) 
Runny nose Yes 28 (8.3%) 0.7 (0.4-1.1) 101 (25.2%) 1.2 (0.9-1.5) 
No 94 (11.6%) 259 (22.6%) 
Headache Yes 64 (13.4%) 1.6 (1.1-2.4) 220 (30.6%) 2.2 (1.7-2.8) 
No 58 (8.7%) 140 (16.9%) 
Muscle aches Yes 66 (19.4%) 3.2 (2.2-4.7) 209 (36.3%) 3.1 (2.4-3.9) 
No 56 (6.9%) 151 (15.6%) 
Altered sense of smell Yes 67 (50.4%) 17.7 (11.5-27.5) 202 (73.5%) 19.5 (14.3-26.9) 
No 55 (5.4%) 158 (12.4%) 
Altered sense of taste Yes 62 (43.4%) 12.0 (7.9-18.4) 206 (70.1%) 16.7 (12.4-22.7) 
No 60 (6.0%) 154 (12.3%) 
Extreme fatigue Yes 63 (21.4%) 3.7 (2.5-5.4) 196 (38.7%) 3.4 (2.6-4.3) 
No 59 (6.9%) 164 (15.8%) 
Diarrhoea Yes 16 (9.8%) 0.9 (0.5-1.5) 66 (33.3%) 1.8 (1.3-2.5) 
No 106 (10.8%) 294 (21.8%) 
Nausea/Vomiting Yes 6 (6.9%) 0.6 (0.2-1.3) 46 (35.1%) 1.9 (1.3-2.8) 
No 116 (10.9%) 314 (22.2%) 
Small itchy red patches on fingers/toes Yes 3 (9.7%) 0.9 (0.2-2.6) 10 (23.8%) 1.0 (0.5-2.0) 
No 119 (10.7%) 350 (23.3%) 
Total 1147 1546 

















aste (OR 16.7, 95% CI 12.4–22.7), and new continuous cough (OR 
.2, 95% CI 1.7–2.9). 
We also noted that date of symptom onset (which related to 
HO classification) was associated with likelihood of seropositiv- 
ty: while 46% of the “suspected” (symptoms after 5 March) group 
ere seropositive, only 10% of “early-probable” (symptoms up to 
 March, which predate the national outbreak) were seropositive 
Figure S3). Of the “uncertain” group, 19% were seropositive, while 
% were seropositive in those reporting no symptoms ( Table 2 ). 157 Overall, amongst those who reported a belief of having had 
OVID-19, characteristics of symptoms reported by Police and Fire 
nd HCW differed compared to HCW-PP. For example, a higher 
roportion reported symptoms fewer than 7 days (39%, 36%, 20% 
espectively) or had a household member with COVID-19 compati- 
le symptoms (25%, 26%, 53% respectively) ( Table 1 ). Thus, we ob- 
erved that those reporting symptoms who were seronegative dif- 
ered in multiple respects from those who reported symptoms and 
ere seropositive. 
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Amongst individuals not reporting any previous COVID-19 com- 
atible symptoms (or any previous PCR test), 158 (8%) were 
eropositive. Amongst these, 81% reported that no household 
ember (or did not know) had any COVID-19 compatible symp- 
oms; together, these data highlight the potential of serology to 
dentify (albeit to an unknown degree), previously unidentified 
symptomatic SARS-CoV-2 infection. 
erological assay performance 
One explanation for the large numbers of symptomatic indi- 
iduals with negative serology might be the sensitivity of the as- 
ays. 7 In our study, anti-Spike (EUROIMMUN) (Anti-S1) indices and 
nti-Nucleocapsid (Roche Elecsys®) (Anti-N) protein assay ratios 
howed a strong positive correlation ( r = 0.93, p < 0.001) and each 
ad a clear bimodal distribution within streams A and B ( Figure 4 ).
There were in total 268 individuals who had previous PCR test 
ositive infection (all 154 from HCW-PP C, plus 24 from Police and 
ire and 90 from HCW) ( Figure 5 , Supplementary Table 1 ). The
ajority were white ( n = 212, 79%) and female ( n = 188, 70%). 4%
 n = 12) had been identified through screening and were asymp- 
omatic at time of swab. 11% had been hospitalised, and all were 158 n average 63 days (IQR 52 – 75 days) post symptom onset. 65% 
ad illness lasting 2 weeks or less (Supplementary Material). Based 
n these 268 individuals, the sensitivity of the anti-S1 and anti-N 
ssays was 93.3% (95% CI 89.6% - 95.7%) and 96.6% (95% CI 93.7% 
 98.2%), respectively. The composite sensitivity (i.e. proportion of 
ositive on at least one assay) was 98.1% (95% CI 95.7% - 99.2%). 
f the 12 individuals who had been asymptomatic when they had 
heir positive PCR test, 8 were seropositive across both assays (Ad- 
itionally, 1 was positive on EUROIMMUN only, while 3 were neg- 
tive across both). 
o antibody assay signals decline? 
There is weak statistical evidence for higher anti-S antibody sig- 
als in individuals with longer illness duration ( p = 0.06; for anti- 
, p = 0.16, Figure 6A, C). There is also evidence for a decline over
ime for anti-S antibody signals with symptom onset to blood sam- 
le intervals of between 35 and 110 days, intervals chosen as they 
nclude 87% of symptomatic known previous PCR positive cases 
 n = 233). Regression models estimate a decline per month of 29.1% 
95% CI 3.1% to 36.7%) (Figure 6B), with similar results in mod- 
ls adjusting for initial illness duration (not shown). There was a 
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imilar trend in anti-N signals (with an estimated 18.7% decline 
er month, 95% CI −26.2% to 36.9%), however this was not sta- 
istically significant (Figure 6D). Over the time period studied, this 
ecline has minimal impact on the serological detection of individ- 
als with microbiologically confirmed COVID-19 disease (Supple- 
entary Table 2). In summary, neither serological assay sensitivity, 
or declining antibody titres, appear to provide an explanation for 
pproximately half of symptomatic individuals who are antibody 
egative in our cohort. 
iscussion 
In summary, in our study of key workers, amongst those with- 
ut prior positive PCR tests, 27% believed they had previously 
ad COVID-19 due to compatible symptoms, but of these, around 
alf lacked any serological evidence of having had the infection. 
mongst individuals who had previously had symptoms, those 
ho were seronegative reported earlier dates of symptom onset, 
horter duration of symptoms and were less likely to report high 
pecificity COVID-19 symptoms of ageusia and anosmia. 
The high proportion of individuals reporting belief they had had 
OVID-19 but who were seronegative did not appear to be readily 159 xplicable by low serological assay sensitivity or rapidly declining 
ntibody titres. We estimated that both immunoassays used had 
igh sensitivity (93.3%, CI 89.6% - 95.7%; and 96.7%, CI 93.7% - 
8.2%, for EUROIMMUN and Roche Elecsys® assays, respectively) in 
he key worker populations studied, who were on average 63 days 
ost PCR-confirmed infection. This is despite many of these indi- 
iduals having had relatively mild disease: amongst the 268 pre- 
iously PCR positive individuals studied, only about 10% had been 
ospitalised. 
A limitation is the retrospective collection of symptoms histo- 
ies, and the potential for recall bias. However, about 97% of the 
ohort provided symptom data naïve to their serological status, 
hich may have reduced the potential for ascertainment bias. Ad- 
itionally, we note that (perhaps due to interest in COVID-19 dur- 
ng the ongoing pandemic, and suspected COVID-19 being a mem- 
rable event) retrospective symptom collection yielded symptom 
nsets which closely mirror the UK outbreak amongst seropositive 
but not seronegative) cases. We also noted that the reporting of 
ymptoms known to be strongly predictive of COVID-19, such as 
ombinations of altered taste and smell, 10 is strongly associated 
ith serostatus, supporting the validity of symptom self reporting. 
n addition, several other self reported factors which are known to 
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ncrease likelihood of infection, such as having had contact with a 
onfirmed/suspected COVID-19 case and having a household mem- 
er who had a positive swab were also associated with seroposi- 
ivity. 
Comparing the data obtained with published data, the test sen- 
itivity estimates we derive are compatible with published results 
or individuals with mild disease (and who had met the thresh- 
ld for testing), 20 , 5 but are higher than those reported by labo- 
atory assessments using smaller panels with few individuals > 
1 days post infection, 15 , 17 likely due to the increased time since 
ymptom onset (median 63 days in this cohort) relative to that in 
revious evaluations. This extended interval has allowed, both an- 
ibody concentrations, and perhaps also affinity of antibodies for 
ARS-CoV-2 21 , 22 to rise over time. Our results are also congruent 
ith reports from anti-Spike S1 Receptor binding domain assays, 23 
nd with neutralisation assays, 16 in that we observed anti-S titres 
ecline over time post infection. We did not observe such signifi- 
ant declines in anti-N immunoassay signals over the time interval 
tudied, but cannot exclude this happening; nevertheless, we can 
xtend the existing literature by showing that these declines have 
inimal impact on assay performance up to 110 days post infec- 
ion in symptomatic key workers. 160 We caution against generalisation to antibody kinetics in other 
opulations, however: the front line key workers we studied, all of 
hom worked during the pandemic, may have been re-exposed to 
ARS-CoV-2 during their work, and may have been serially boosted 
y re-exposure to virus leading to sustained antibody responses, as 
oted with other viral pathogens. 24 
In conclusion, this study indicates that a substantial propor- 
ion of key workers believe that they have had COVID-19 based 
n symptoms experienced during the first wave of the pan- 
emic in the UK, but had no antibodies detectable a median of 
3 days since symptom onset, despite high immunoassay speci- 
city and limited reduction of antibody titres over the study 
eriod. 
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